Bayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it tries to close the gap with Merck & Co's rival drug gefapixant. The pharma company said last ...

Bethan Galliers was delighted to be at the theatre with friends for a play she'd wanted to see for ages. But within minutes her enjoyment was rudely interrupted by a violent coughing fit — her own.

The FDA has issued a complete response letter (CRL) to Merck & Co's gefapixant candidate for refractory chronic cough, delaying the programme and giving Bayer an opportunity to close the gap with ...

Analyst Serge Belanger from Needham maintained a Buy rating on Trevi Therapeutics (TRVI – Research Report) and keeping the price target at ...

Two trials of a new drug have shown that at low doses, it can ease the often distressing symptoms of chronic cough with minimal side effects. Principle researcher Jacky Smith, a Professor of ...

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report) on January 10 and set a price ...